Promising Outlook for Prothena: Buy Rating Backed by Innovative CYTOPE Platform Advancements
I'm PortAI, I can summarize articles.
Prothena received a Buy rating from analyst Andrew Fein of H.C. Wainwright, with a $30 price target, due to advancements in its CYTOPE platform. The platform's ability to deliver macromolecules intracellularly shows promise for treating neurodegenerative diseases like ALS and FTD. Its potential for collaborations and crossing the blood-brain barrier enhances its value. Piper Sandler also maintained a Buy rating with a $36 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments